EFFECT OF GRANULOCYTE COLONY-STIMULATING FACTOR ON NEUTROPENIA AFTER CHEMOTHERAPY IN ACUTE MYELOID LEUKEMIA

DOI Web Site

Bibliographic Information

Other Title
  • 急性骨髄性白血病における化学療法後の好中球減少症に対するＧ‐ＣＳＦ投与の効果
  • キュウセイ コツズイセイ ハッケツビョウ ニ オケル カガク リョウホウ ゴ ノ コウチュウキュウ ゲンショウショウ ニ タイスル G-CSF トウヨ ノ コウカ

Search this article

Description

The widespread clinical use of granulocyte colony-stimulating factor (G-CSF) has made it possible to employ more powerful chemotherapy to treat malignant neoplasms including leukemia and malignant lymphoma. On the other hand, it has been feared that G-CSF may promote the proliferation of leukemic cells in acute myeloid leukemia (AML). We administered G-CSF to patients with neutropenia after remission induction therapy for AML, and assessed the efficacy and safety of this agent, as well as the effect on the response rate and survival. The subjects were 51 patients with AML aged 15-69 years who underwent initial remission induction therapy and who were registered between May 1993 and April 1995 (G-CSF, 32; control, 19). There were no significant differences in the response rate, survival rate, and disease-free survival rate between the patients given G-CSF and those not given it. The time required for the neutrophil count to return to 1000/μl was 7 days (3-19 days) in the G-CSF group versus 15 days (3-31 days) in the control group, and the difference was significant (p<0.01). These result suggest that G-CSF is useful for treatment of neutropenia after remission induction therapy without adversely influencing the prognosis of AML.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top